Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for…
DESTINY-Breast05 Phase III Trial Demonstrates ENHERTU® Significantly Reduces Recurrence Risk in High-Risk HER2-Positive Early Breast Cancer Positive results from the DESTINY-Breast05 Phase III trial have demonstrated that ENHERTU® (fam-trastuzumab deruxtecan-nxki) provides a highly statistically significant and clinically meaningful improvement in…
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Shows Durable 5-Year Survival Benefit Over Chemotherapy in Advanced Endometrial Carcinoma Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced updated five-year follow-up data from the pivotal Phase…
Water- en Energiebedrijf Aruba N.V. (WEB) and Seven Seas Water Group, a leading multinational provider of Water-as-a-Service® (WaaS®) solutions, have officially broken ground on a new state-of-the-art seawater reverse osmosis (SWRO) desalination plant in Aruba. The project marks a major…
Diorasis Therapeutics, a biotechnology company pioneering durable gene therapies for glaucoma and other ophthalmic diseases, today announced the appointment of Dimitri Azar, MD, MBA, AM (hon.), DHL (hon.), to its Board of Directors. Dr. Azar is a globally recognized leader…
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, operating in the U.S. and Canada, has announced a landmark agreement with the administration of President Donald J. Trump to broaden access to in vitro fertilization (IVF) therapies for the…
ME Therapeutics Holdings Inc., a publicly listed biotechnology company focused on developing innovative cancer therapies in the field of immuno-oncology, today announced a significant milestone in its in vivo CAR cell therapy program. The Company’s subsidiary, ME Therapeutics Inc., has…
Y.ora Vision, Inc., a newly established ophthalmic medical device company and a spoke company of Eyexora, has officially announced the signing of a licensing agreement between the Singapore Eye Research Institute (SERI) and Eyexora Global. The agreement is set to…
Scanogen Inc., a molecular diagnostics company at the forefront of next-generation infectious disease detection, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its rapid assay designed to identify bloodstream infection pathogens directly from…
WaHa Inc. proudly celebrates its co-founder, Professor Omar M. Yaghi, recipient of the 2025 Nobel Prize in Chemistry, awarded by the Royal Swedish Academy of Sciences. The global scientific community recognizes Professor Yaghi’s groundbreaking contributions to reticular chemistry—a field he…